
Sanofi weighs ~$40B acquisition of Insmed in potential largest pharma deal of 2026 | Gif: NEXTonFOX on Giphy
All the top Biotech & Pharma news in one daily newsletter.
Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣
✅ The Good News ✅
THE GOOD
Approvals & Labels
ViiV Healthcare gains CHMP backing to expand Tivicay and Dovato use in paediatric HIV patients
Small molecule, infectious disease, pediatric HIV, regulatory - Read more
THE GOOD
Business Development & Partnerships
Arcera Life Sciences, Innogen strike $1B+ GLP-1 licensing deal for Africa, Eastern Europe, Latin America, Middle East
Licensing deal, metabolic disease, GLP-1, milestone payments, royalties, commercialization - Read more
Lupus Research Alliance, Lupus Therapeutics, AstraZeneca collaborate to advance lupus drug development and clinical trial recruitment
Research collaboration, autoimmune, cell therapy, clinical trials, patient engagement - Read more
Sonic Incytes, Madrigal Pharmaceuticals partner on multi-year non-invasive liver assessment initiative for MASH patients
Research collaboration, diagnostics, AI/ML, liver disease, point-of-care - Read more
PRESENTED BY SCIENCE 2 SALES
Outbound and commercial intelligence built exclusively for selling into biopharma.

Science 2 Sales is the outbound engine for companies selling into biotech & pharma. We handle the market intelligence, prospect scoring, email sequences, LinkedIn outreach, and cold calling - so your sales team inherits a full calendar of qualified meetings.
Built by biopharma BD & sales reps, exclusively for biopharma commercial teams. It’s the platform and service we wish we had years ago.
✅ More Good News ✅
THE GOOD
Clinical Trials
Erasca's ERAS-0015 shows 44% response in Ph1, advancing to Ph3 for KRAS-mutated pancreatic cancer
Small molecule, cancer, molecular glue, pancreatic cancer, KRAS mutation, non-small cell lung cancer - Read more
Merck & Co., Kelun-Biotech's (sacituzumab tirumotecan) TROP2 ADC meets Ph3 overall survival endpoint in advanced gastroesophageal adenocarcinoma
Antibody drug conjugate, cancer, TROP2, gastroesophageal cancer, sacituzumab tirumotecan - Read more
Revolution Medicines' Rasonque (daraxonrasib) shows 60.7% response rate in first-line pancreatic adenocarcinoma in Ph1/2 trial
Small molecule, cancer, KRAS inhibitor, pancreatic cancer, combination therapy, first-line treatment - Read more
BioVersys, GSK's alpibectir (AlpE) shows bactericidal activity in Ph2a study for pulmonary tuberculosis
Small molecule, infectious disease, tuberculosis, antibiotic, drug-resistant bacteria, combination therapy - Read more
THE GOOD
Fundraises
Asgard Therapeutics receives €2.5M ($2.74M) EIC Accelerator grant, advancing cancer immunotherapy toward clinical trials
Cancer immunotherapy, gene therapy, cell reprogramming, preclinical - Read more
MegaRobo Technologies raises nearly $200M, advancing AI-driven laboratory automation platform
AI-driven, laboratory automation, drug discovery, platform technology - Read more
THE GOOD
Mergers & Acquisitions
Sanofi weighs ~$40B acquisition of Insmed in potential largest pharma deal of 2026
Small molecule, respiratory, strategic, major transaction - Read more
THE GOOD
Regulatory
FDA launches CBER Safety Council to oversee post-market vaccine and cell and gene therapy safety
Cell and gene therapy, vaccines, regulatory, operational - Read more
PRESENTED BY YOU?
Get the attention of 3000+ Biotech & Pharma Professionals 🤩

Gif: mostexpensivest on Giphy
Do you offer a biotech/pharma-focused product or service?
Or looking to get investor/analyst interest on your budding start-up?
Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.
Just reply to this email* or message me on LinkedIn to learn more.
*If you’re reading this on the web version, email [email protected]
❌ The Bad News ❌
THE BAD
Clinical Trials
Celldex's barzolvolimab (anti-KIT) fails Ph2 in atopic dermatitis, halting development in indication
Antibody, autoimmune, small molecule, monoclonal antibody, atopic dermatitis, ocular pain - Read more
THE BAD
Layoffs
Novo cuts additional 215 New Jersey jobs amid ongoing US sales organization restructuring
Small molecule, metabolic disease, cost reduction, operational - Read more
THE BAD
Regulatory
FDA misses second deadline for Savara's Molbreevi (molgramostim) review for autoimmune pulmonary alveolar proteinosis
Protein therapy, autoimmune, pulmonary alveolar proteinosis, rare lung disease, inhaled therapy, molgramostim - Read more
FDA delays decision on Belite Bio's (tinlarebant) new drug application for Stargardt disease type 1 to May
Small molecule, ophthalmology, Stargardt disease, retinol transport inhibitor, rare disease - Read more
You’re all caught up on the latest Pharma & Biotech News!
TLDR Biotech wants to hear from you! 📣
Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝
If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️
And lastly - connect with me on LinkedIn!

Thanks for reading! -Anis
Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here


